MEDVi Alternatives for GLP‑1: The 5 Best Options in 2026

Published: July 17, 2026 · Last reviewed: July 17, 2026

By The RX Index Editorial Team

Independent guidance for choosing your GLP‑1 path. This guide is general information, not medical advice. Talk to a licensed clinician before you start, stop, or change any medication.

The best MEDVi alternative for GLP‑1 care depends on why you’re switching. Embody is the leading low-cost compounded pick — injections from $79/month, no membership fee, plus a needle-free gum. Ro is strongest for an FDA-approved medication and insurance help. Yucca is the clearest no-video-visit option at $146/month on a six-month semaglutide plan. Your state, medication type, and commitment change the answer.

One quick note before the table: compounded and FDA-approved are two different things (we explain below), and buying an FDA-approved brand is cheaper than it was a year ago. Match your reason to the right option and you’ll pick the winner the first time.

The RX Index is the independent GLP‑1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

A quick safety note before any provider link below: this page compares programs, costs, and treatment paths — it does not decide whether a medication, formulation, or dose is right for you. Read the FDA-approved product’s prescribing information (or a compounded product’s pharmacy and prescriber disclosures) and talk to a licensed clinician about your health history, other medications, pregnancy, and side effects.

Why are people leaving MEDVi?

People usually leave MEDVi for one of five reasons: the price steps up after the first month, a billing or cancellation headache, slow shipping, wanting an FDA-approved medication, or wanting a different format like a pill or a needle-free option. Match your reason to the fix and you’ll choose the right replacement the first time.

We read through current public reviews for recurring themes. They’re a mix — real praise sits next to real complaints about billing, cancellation, and shipping timing. Those are service-pattern signals, not proof of medical quality or typical results. But the pattern rhymes with what sends people searching: someone signs up for a $179 first month, then the card gets hit for a higher refill and the sticker shock does it. Someone waits on a shipment. Someone finds cancellation clunky. And a growing group saw the FDA headlines and thought, “wait — is this even safe?”

Here’s the honest read on each reason:

• “The price stepped up.” MEDVi’s intro price is real, but the refill rate is higher, and its cheapest deal generally means a longer prepay. A no-membership compounded plan — or buying an FDA-approved drug direct — can beat it.
• “Billing or cancellation was a hassle.” MEDVi programs auto-renew, and you have to cancel at least 72 hours before your next billing date. If admin was your problem, pick a plan with clean cancel-anytime terms and confirm them before you enter a card.
• “Shipping was slow.” Some alternatives ship faster — Yucca says approved orders go by UPS 2-Day Air on most orders. That’s a documented method, not a promise every order beats MEDVi, but speed is a fair reason to switch.
• “I want FDA-approved, not compounded.” Valid — and now more affordable than most people think. (More on that below. And heads-up: MEDVi itself now lists some branded options too, so you may not even have to leave.)
• “I want a pill or no needles.” There are real options here, from a compounded gum to FDA-approved pills.

Two of these reasons deserve their own sections, because they’re the ones that keep people up at night: the FDA letter and the money. Let’s take them head-on.

What did the FDA warning letter to MEDVi actually say?

Let’s define the key word. Misbranding is an FDA term for a drug whose labeling or advertising is false or misleading. It’s a marketing-and-claims problem. It is not the FDA finding that a batch of medicine was unsafe, and it is not an order to shut down.

What the FDA specifically flagged, per the letter:

• Website language that made it sound like MEDVi was the pharmacy compounding the drugs.
• “Same active ingredient” claims that implied the FDA had approved or evaluated MEDVi’s compounded products.
• The FDA warned that not fixing the problems could lead to further action such as seizure or an injunction, and said the letter wasn’t a complete list of every possible violation.

What the letter does not prove — and this matters if you’re anxious:

• It does not prove every MEDVi patient got an unsafe product.
• It does not prove every prescription was illegal.
• It did not ban MEDVi from operating.
• It does not tell any individual to stop their medication.
• It does not automatically make any other provider “safe.”

The fair context: this wasn’t a MEDVi-only crackdown. The FDA announced 30 warning letters to telehealth companies on March 3, 2026 (the letters were dated February 20) over the same issue — sites implying compounded GLP‑1s are the same as FDA-approved drugs, or hiding who actually compounded them. The whole compounded category is under a brighter spotlight right now. So the takeaway isn’t “run from MEDVi and trust anyone else.” It’s “hold every provider to the same standard.”

Here’s a small thing you’ll notice: nowhere on this page do we say a compounded drug is the “same active ingredient” as a brand. That’s not an accident — it’s the exact phrase the FDA went after. When a company promises you a compounded shot is identical to Wegovy, treat it as a yellow flag, not a selling point.

Should you pick an FDA-approved or a compounded MEDVi alternative?

Choose the type of medication before you choose the provider. FDA-approved drugs (like Wegovy and Zepbound) have passed the FDA’s full review for their approved uses. A compounded drug is custom-mixed by a licensed pharmacy for an individual patient — it’s not FDA-approved, and the FDA doesn’t check it for safety, effectiveness, or quality before it’s sold. Both can be part of legitimate care, but they aren’t the same thing, and the price gap between them has narrowed a lot in 2026.

The reason most people chose compounded is fading. Two years ago, brand-name GLP‑1s cost over $1,000/month, so compounded was the only affordable door. In late 2025 and 2026, the drugmakers cut cash prices hard:

• Zepbound (tirzepatide) through LillyDirect is now $299/mo (2.5 mg), $399/mo (5 mg), and $449/mo (7.5–15 mg, when you refill within 45 days).
• Wegovy (semaglutide) through NovoCare is $349/mo for standard doses, with a $199/mo intro on the two lowest doses.
• The Wegovy pill starts around $149/mo.

The point isn’t that brand and compounded prices are now equal — a bare-bones compounded plan like Embody still starts lower ($79/mo). The point is that an FDA-approved drug is no longer automatically a $1,000-a-month choice. For many people, it’s now a real option worth comparing — and with insurance, it can be the cheapest of all.

• Pick FDA-approved if the regulatory question bothers you, you want a medicine that’s been through full FDA review, or you have insurance that might cover it. Your best fits are Ro, Sesame, or buying direct from the drugmaker.
• Consider a compounded treatment path if you want the lowest cash price or a format the brands don’t offer — and a licensed prescriber agrees it fits your situation, you understand the finished product isn’t FDA-approved, and the provider clearly discloses the prescriber, pharmacy, price, and formulation. Your best fits are Embody or Yucca.

Does MEDVi itself now offer FDA-approved options?

Yes. MEDVi’s current site also lists branded FDA-approved paths — Wegovy pill, Wegovy injection, and Zepbound injection — at a $99 membership plus the medication cost. So if your only reason for leaving is that you want an FDA-approved drug, ask MEDVi for its current all-in branded price first, then compare it against Ro, Sesame, and buying direct. You might not need to switch at all.

What are the 5 best MEDVi alternatives for GLP‑1 in 2026?

The five strongest alternatives each solve a different reason for leaving MEDVi: Embody for low-cost or needle-free compounded care, Yucca for no-visit compounded value, Ro for FDA-approved care with insurance help, Sesame for FDA-approved care where you pick your doctor, and buying direct for the lowest cash price on an FDA-approved drug. They’re ranked by fit, not by which one pays us.

We keep the two categories visibly separate below, on purpose — because blurring them is exactly what got MEDVi in trouble.

Compounded treatment paths

FDA-approved treatment paths

How much do MEDVi alternatives really cost?

You can’t judge cost by the first-month price — that’s the trap. On sticker price, a no-membership compounded plan is usually lowest (Embody starts at $79/month), while Yucca’s six-month semaglutide plan runs $146/month. FDA-approved direct pricing is now $299–$449/month — no longer the $1,000 option it used to be, and with insurance it can be the cheapest of all. Always compare the ongoing price, not the hook.

Everything was checked in July 2026. Remember: intro prices are bait; ongoing prices are the truth. Confirm your exact number at each provider’s checkout.

A price question everyone asks: does a higher dose cost more? It depends on the provider. Embody’s price is flat within your plan. Some others price by plan length only; manufacturer-direct prices do rise by dose. Always confirm your maintenance-dose price before you commit.

Another one: does HSA/FSA make it cheaper? Not exactly. An HSA or FSA may let an eligible person pay or get reimbursed with pre-tax dollars, subject to the account’s rules — it’s a payment method, not insurance coverage. It can lower your effective cost, but it doesn’t mean an insurer is covering the drug.

The bottom line on money: compounded still has the lowest sticker price. FDA-approved brands have fallen enough to be a realistic option for far more people — and if you have commercial insurance, Ro’s concierge can make an FDA-approved drug the cheapest path overall and give you a medicine that’s been through full FDA review. That’s a genuinely better deal than it was in 2024.

How do cancellation and refund terms compare?

Cancellation terms differ almost as much as prices, so check them before you enter a card. MEDVi requires 72 hours’ notice before billing and generally doesn’t refund the current period; Embody uses a 72-hour cancellation window but multi-month bundles can commit you to the plan term; Yucca’s refund options narrow once your prescription is processed; and manufacturer-direct purchases follow the maker’s own return rules. The deadline, the commitment length, and the pharmacy-processing cutoff are the three things that decide whether you get charged again.

The safest move for anyone worried about being double-charged: confirm your next MEDVi billing date, get the controlling cancellation deadline for your new plan in writing, and don’t cancel MEDVi until your new plan is confirmed. We walk through that timing below.

Which MEDVi alternatives are available in my state?

Availability changes by state, by medication, and by prescriber — a national-looking provider may not offer every option everywhere. Don’t treat a general “available in most states” line as nationwide coverage. Use each provider’s own eligibility check, or The RX Index’s Find My GLP‑1 Path tool, to confirm before you commit.

State rules matter most for compounded treatment paths, where the prescriber has to be licensed where you live and the specific formulation has to be available. Among the options here, Ro and Sesame operate nationwide, Yucca Health says it has licensed providers in all 50 states, and LillyDirect and NovoCare are available in most states as direct-to-patient programs. Always confirm your exact treatment during intake.

How do you switch from MEDVi without paying twice?

You can switch providers, but no comparison page can promise uninterrupted treatment or preserved results — timing, eligibility, your prescribed plan, billing, and shipping all have to be coordinated with your current and new clinicians. MEDVi auto-renews and requires cancellation at least 72 hours before your billing date, and generally doesn’t refund the current period, so line up your new provider first and cancel at the right moment. Rushing either end is how people get double-charged or hit a gap.

1. 1

   Find your dates.

   Log into MEDVi and note your next billing date, whether a refill has already been processed or shipped, and your subscription term. This tells you how much runway you have.

2. 2

   Complete the new provider’s clinical review before you cancel.

   Enrollment isn’t approval, approval doesn’t guarantee fulfillment, and the new clinician may not continue the same medication or dose. Don’t cancel MEDVi until your new plan is confirmed — when your clinicians agree continuity is appropriate and you understand any billing overlap.

3. 3

   Ask MEDVi one specific question.

   Something like: “Has a refill already been sent to the pharmacy, and is any part of my current charge still refundable?” MEDVi generally doesn’t refund the current or prior period, and medication usually can’t be returned once ordered — so knowing where your refill stands protects your wallet.

4. 4

   Cancel through an accepted channel and save proof.

   MEDVi lets you cancel by email or portal chat, at least 72 hours before billing. Screenshot everything — the request, the confirmation, the date, any ticket number.

5. 5

   Gather your records for the new clinician.

   Have a photo of your prescription label, your current medication and dose, your most recent dose date, and your insurance card if you’re seeking coverage. This gives the new clinician what they need to make a decision.

6. 6

   Don’t change your treatment on your own.

   Do not stop, restart, overlap doses, or change timing based on anything you read online — including this page. Ask the prescribing clinician how to handle the timing.

One reason continuity is worth coordinating carefully: stopping a GLP‑1 abruptly is commonly followed by weight regain — that’s how the drug class tends to work, not a provider-specific flaw — so a planned handoff beats an accidental gap. Your clinicians can tell you how to time it.

Can you keep your current dose when you switch?

Maybe — but it’s not guaranteed. A new provider may review your current prescription and history, but they decide whether to continue, change, or restart your dose after weighing your records, tolerance, the medication type, and time since your last dose. Some programs restart new patients at the lowest dose; others will consider continuing your dose if you show a current prescription. Always tell your new clinician exactly what you’re on.

Bring the proof (prescription label, dose, last dose date), ask directly whether they’ll continue your dose before you pay, and confirm the displayed price still applies to the plan they actually prescribe. The clinician makes the final call — that’s a safety feature, not red tape.

Should you just stay with MEDVi?

Sometimes, yes. MEDVi can still be reasonable if your care is working, you understand and accept the recurring price, your shipments arrive fine, and you’re comfortable with your medication type — and remember MEDVi now lists branded FDA-approved paths too, so wanting an FDA-approved drug isn’t automatically a reason to leave. Switching only makes sense if it fixes a real problem — chasing a lower intro price can land you right back where you started. Be honest about why you’re leaving before you go.

We’re an affiliate site, and we still mean this: don’t switch just to switch. Use this quick gut-check.

How did The RX Index choose these MEDVi alternatives?

We evaluate every provider under the RX Index Score framework — five pillars, always in this order: clinical legitimacy, care quality, transparency, access, and cost. Commission never turns an unverified price or a poor-fit provider into a winner; every recommendation traces back to the dated facts on this page. When two options are genuinely comparable, fit for your reason for leaving breaks the tie — not who pays us.

• Clinical legitimacy — Is there a real licensed prescriber? Is the medication type disclosed honestly? Any regulatory red flags? (This is where the FDA’s cited MEDVi marketing language lowers its transparency and legitimacy marks — and why we won’t repeat “same active ingredient.”)
• Care quality — Real intake, follow-up access, a way to reach a human, and clear escalation if something goes wrong.
• Transparency — Intro and ongoing prices, membership-vs-medication split, commitment length, cancellation cutoff, refund rules, and who’s dispensing your medicine.
• Access — State availability, live-vs-async care, insurance support, format options, and shipping.
• Cost — Month-one, six-month, and longer totals; what’s due upfront; and your financial risk if you cancel.

Our evidence order is simple: the FDA and other regulators first, then official provider terms and live pricing pages, then pharmacy and clinical disclosures, then current review profiles for service patterns, then individual comments only as illustration — and our editorial judgment on top of all of it. We’re not publishing a single numerical score on this page until every input, weight, and verification date behind it is visible.

On affiliate links: we disclose them, and payout doesn’t decide our verdict. A partner we earn from can lose a recommendation if the evidence or your fit doesn’t support it, and we never route FDA-approved intent to a compounded product just because the commission is bigger.

See a price, policy, or availability detail that’s changed? Tell us at [email protected] and we’ll re-check and update the verification date.

Frequently asked questions about MEDVi alternatives

What is the best MEDVi alternative for GLP-1?

There's no single best one for everyone. Embody is the leading low-cost, no-membership, or needle-free compounded pick; Ro is best for FDA-approved medication with insurance help; Yucca is best for no-visit compounded value with a six-month price.

What is the cheapest alternative to MEDVi?

On sticker price, a no-membership compounded plan is usually lowest -- Embody starts at $79/month, though the refill rate steps up after month one, and Yucca's six-month semaglutide plan runs $146/month. FDA-approved direct pricing is now $299-$449/month, and with insurance it can drop to as little as $25/month.

How much does MEDVi cost after the first month?

MEDVi's compounded semaglutide starts around $179 for the first month, then a higher refill rate (widely reported near $299/month, with lower pricing tied to longer prepay). Its current site also lists branded Wegovy and Zepbound paths at a $99 membership plus medication. Confirm the current number in checkout before you commit.

Did the FDA ban MEDVi?

No. The FDA sent MEDVi a warning letter in February 2026 about misleading marketing on its website -- a claims-and-labeling issue, not a ban and not a finding that its medicine was unsafe. MEDVi's letter was one of 30 the FDA sent to telehealth companies over the same kind of marketing.

Is MEDVi's medication FDA-approved?

It depends on the product. MEDVi's compounded semaglutide and tirzepatide programs are not FDA-approved as finished products. MEDVi's current site also lists branded Wegovy pill, Wegovy injection, and Zepbound injection paths at a $99 membership plus medication cost; those named products are FDA-approved, subject to indication, eligibility, and availability.

Are compounded GLP-1 medications the same as Wegovy or Zepbound?

No -- and it's a compliance problem to say they are. Wegovy and Zepbound are specific FDA-approved products. A compounded prescription is custom-mixed by a pharmacy, is not FDA-approved or pre-reviewed by the FDA, and is not the same as an FDA-approved generic.

Can I use insurance with a MEDVi alternative?

Ro is the best pick on this list for insurance and prior-authorization help. Support doesn't guarantee your plan will cover the drug, but if it does and you meet the savings-program rules, an FDA-approved GLP-1 can drop to as little as $25/month. Compounded programs are almost always cash-pay only.

Can I transfer my MEDVi prescription?

Don't count on a direct transfer. A new clinician may use your old prescription and records as a reference, but they have to independently evaluate you and write a new prescription if it's appropriate.

Can I keep my current dose when I switch from MEDVi?

Possibly, but it's not guaranteed. Some providers restart new patients at the lowest dose; others will consider continuing your dose if you show a current prescription. Your new clinician decides after reviewing your records.

Should I cancel MEDVi before joining another provider?

Check two things first: your next MEDVi billing date and whether the new provider has actually approved you. Cancel too late and you get charged again; assume approval too early and you risk a gap in treatment. Line up the new plan, then cancel at least 72 hours before billing.

Which alternative offers a pill or no-needle option?

For compounded, Embody offers a needle-free GLP-1 gum. For FDA-approved pills, Ro and Sesame carry the Wegovy pill and Foundayo. Compounded oral or needle-free products and FDA-approved pills are different categories -- don't treat them as interchangeable.

Which alternative doesn't require a live video visit?

Yucca uses an asynchronous model -- a licensed provider reviews your intake (usually within 24 hours) with no scheduled video visit, subject to approval and your state's rules.

Which provider is available in my state?

Availability changes and depends on the medication, prescriber, and treatment path. Use the Find My GLP-1 Path tool at therxindex.com/find-my-path/ or the provider's own eligibility check rather than assuming a provider covers every state.

Is a six-month plan always cheaper?

Not necessarily. A lower monthly-equivalent price saves money only if the treatment stays appropriate for you and you're comfortable with the commitment and the tighter refund rules that usually come with it.